Transcriptomic meta-analysis in bipolar disorder identifies mitochondrial, synaptic, and inflammatory pathway genes
This meta-analysis integrated publicly available transcriptomic datasets from 917 postmortem brain samples (386 bipolar disorder patients, 531 controls) and 638 peripheral blood samples (316 BD patients, 322 controls). The analysis aimed to identify differentially expressed genes (DEGs) across brain and blood in BD. No specific intervention or exposure was studied; the comparator was control samples from individuals without BD.
The main results showed enrichment of genes involved in mitochondrial bioenergetics and oxidative stress, synaptic structure, signaling, and neuroinflammatory pathways. The analysis also identified several novel long non-coding RNAs, microRNAs, and small nucleolar RNAs not previously linked to BD, including SNORD62B, SNORA70, and SNORA10. DrugBank annotation highlighted pharmacologically actionable genes such as SST, P2RY12, and C3. No effect sizes, absolute numbers, p-values, or confidence intervals were reported for these findings.
Safety and tolerability data were not reported, as this was an analysis of transcriptomic data. Key limitations were not explicitly stated in the input. The practice relevance is restrained: this meta-analysis provides candidate biomarkers and druggable targets (e.g., SST) to guide future mechanistic and therapeutic studies. The findings are associative from observational transcriptomic studies and do not demonstrate causation, clinical outcomes, or direct therapeutic application.